Free Trial

Coherus BioSciences (CHRS) Stock Forecast & Price Target

$1.64
+0.07 (+4.46%)
(As of 07/19/2024 ET)

Coherus BioSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 6 Wall Street analysts who have issued ratings for Coherus BioSciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for CHRS.

Consensus Price Target

$8.67
428.46% Upside
High Forecast$12.00
Average Forecast$8.67
Low Forecast$6.00

According to the 6 analysts' twelve-month price targets for Coherus BioSciences, the average price target is $8.67. The highest price target for CHRS is $12.00, while the lowest price target for CHRS is $6.00. The average price target represents a forecasted upside of 428.46% from the current price of $1.64.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.67$8.83$9.29$15.57
Forecasted Upside428.46% Upside206.91% Upside185.79% Upside145.93% Upside
Get Coherus BioSciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

CHRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CHRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Coherus BioSciences Stock vs. The Competition

TypeCoherus BioSciencesMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside428.46% Upside1,426.46% Upside10.02% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/1/2024Robert W. Baird
2 of 5 stars
 Lower TargetOutperform ➝ Outperform$9.00 ➝ $8.00+362.43%
5/24/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00+497.01%
5/13/2024Truist Financial
1 of 5 stars
 Lower TargetBuy ➝ Buy$8.00 ➝ $7.00+258.97%
11/8/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
10/23/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$8.00 ➝ $7.00+112.12%
10/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$7.00 ➝ $6.00+59.57%
7/24/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$12.00+179.72%
3/28/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$11.00+83.33%
3/14/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$21.00 ➝ $23.00+261.07%
11/14/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$13.00 ➝ $11.00+41.21%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:14 AM ET.

CHRS Forecast - Frequently Asked Questions

What is Coherus BioSciences' forecast for 2024?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Coherus BioSciences is $8.67, with a high forecast of $12.00 and a low forecast of $6.00.

Should I buy or sell Coherus BioSciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CHRS shares.

Does Coherus BioSciences's stock price have much upside?

According to analysts, Coherus BioSciences's stock has a predicted upside of 214.42% based on their 12-month stock forecasts.

What analysts cover Coherus BioSciences?

Coherus BioSciences has been rated by research analysts at HC Wainwright, Robert W. Baird, and Truist Financial in the past 90 days.

Do Wall Street analysts like Coherus BioSciences more than its competitors?

Analysts like Coherus BioSciences more than other "medical" companies. The consensus rating score for Coherus BioSciences is 2.83 while the average consensus rating score for "medical" companies is 2.72. Learn more on how CHRS compares to other companies.


This page (NASDAQ:CHRS) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners